New York State Common Retirement Fund
ZNTL icon

New York State Common Retirement Fund’s Zentalis Pharmaceuticals ZNTL Stock Holding History

New York State Common Retirement Fund’s Portfolio ZNTL Stock Details ZNTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$75.2K Buy
+15,500
New +$61.9K ﹤0.01% 2829
2025
Q2 		– Sell
-21,891
Closed -$34.8K – 3357
2025
Q1 		$34.8K Hold
21,891
– – ﹤0.01% 2879
2024
Q4 		$66.3K Hold
21,891
– – ﹤0.01% 2759
2024
Q3 		$80.6K Hold
21,891
– – ﹤0.01% 2695
2024
Q2 		$89.5K Buy
21,891
+9
+0% +$101 ﹤0.01% 2918
2024
Q1 		$345K Sell
21,882
-51
-0.2% -$701 ﹤0.01% 2218
2023
Q4 		$332K Sell
21,933
-80
-0.4% -$1.17K ﹤0.01% 2249
2023
Q3 		$442K Buy
22,013
+250
+1% +$6.35K ﹤0.01% 2108
2023
Q2 		$614K Sell
21,763
-2,231
-9% -$53.5K ﹤0.01% 1986
2023
Q1 		$413K Sell
23,994
-9,704
-29% -$197K ﹤0.01% 2271
2022
Q4 		$679K Buy
33,698
+57
+0.2% +$1.23K ﹤0.01% 2166
2022
Q3 		$729K Sell
33,641
-85,560
-72% -$2.34M ﹤0.01% 2143
2022
Q2 		$3.35M Sell
119,201
-76
-0.1% -$2.01K ﹤0.01% 1387
2022
Q1 		$5.5M Buy
119,277
+1,925
+2% +$104K 0.01% 1241
2021
Q4 		$9.87M Buy
117,352
+93,289
+388% +$7.22M 0.01% 1004
2021
Q3 		$1.6M Sell
24,063
-5,184
-18% -$299K ﹤0.01% 1878
2021
Q2 		$1.56M Buy
29,247
+2,247
+8% +$120K ﹤0.01% 2018
2021
Q1 		$1.17M Buy
27,000
+1,900
+8% +$81.8K ﹤0.01% 2056
2020
Q4 		$1.3M Buy
25,100
+15,600
+164% +$704K ﹤0.01% 1910
2020
Q3 		$311K Hold
9,500
– – ﹤0.01% 2452
2020
Q2 		$456K Buy
+9,500
New +$364K ﹤0.01% 2270

Other funds holding ZNTL

5VM
5AM Venture Management San Francisco, California $288M AUM 313.93% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $322M AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

New York State Common Retirement Fund's ZNTL Position: Q2 2026 in Review

New York State Common Retirement Fund opened a new position in Zentalis Pharmaceuticals (ZNTL) in Q2 2026: 15,500 shares worth $75.2K. The stake represents ﹤0.01% of the portfolio and ranks #2829 among its holdings. This is a return to the name: New York State Common Retirement Fund previously reported a position in ZNTL as recently as Q1 2025.

New York State Common Retirement Fund first reported a position in ZNTL in Q2 2020 and has held it in 21 quarters since. The position peaked at $9.87M in Q4 2021. 114 funds tracked by Wall St. Rank hold ZNTL as of Q2 2026.

  • New York State Common Retirement Fund held 15,500 shares of Zentalis Pharmaceuticals worth $75.2K as of Q2 2026.
  • Zentalis Pharmaceuticals was a new New York State Common Retirement Fund position in Q2 2026.
  • Zentalis Pharmaceuticals made up ﹤0.01% of New York State Common Retirement Fund's portfolio in Q2 2026, its #2829 holding.
  • New York State Common Retirement Fund first reported a position in Zentalis Pharmaceuticals in Q2 2020 and has held it in 21 quarters since.
  • New York State Common Retirement Fund's Zentalis Pharmaceuticals position peaked at $9.87M in Q4 2021.
  • 114 funds tracked by Wall St. Rank held Zentalis Pharmaceuticals as of Q2 2026.

Based on New York State Common Retirement Fund's 13F filing for Q2 2026, filed 29 Jul 2026.